Sector News

Seattle Genetics on a ‘great trajectory,’ looks to grow staff by 100

April 24, 2015
Life sciences
Seattle Genetics is hiring for 100 positions, Chief Operating Officer Eric Dobmeier said Thursday.
 
The Bothell-based biotech company (Nasdaq: SGEN) is looking to fill positions ranging from biostatisticians and research associates to the head of its cancer research program and vice president of marketing.
 
That growth is to keep the company, which develops cancer treatments, on track with what a Seattle Genetics spokeswoman called a “great trajectory.”
 
Hiring new people will also coincide with the company ramping up spending in coming years to support preclinical developments, clinical trial activities and continue the commercialization of its flagship product Adcetris, according to a recent filing with the Securities and Exchange Commission. Adcetris is used to treat lymphoma.
 
Seattle Genetics is also investing heavily in its pipeline. That was one factor that led to a $27 million loss in the fourth quarter last year.
 
Even after that loss, though, the company’s stock held steady. Today it is trading at about $37 per share.
 
The company will report first quarter earnings next week.
 
By Annie Zak
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).